Is Biogen (BIIB) Fully Priced After Earnings Raised Revenue But Cut Profit?

Biogen (BIIB) recently reported Q2 2026 earnings with higher sales but lower net income, raising questions about its current valuation. Despite a 61.47% shareholder return over the past year, the stock is considered 9.4% undervalued by analysts based on long-term growth for its Alzheimer's drug LEQEMBI. However, its P/E ratio of 36.5x is significantly higher than industry averages, suggesting a premium that warrants careful consideration of both potential risks and rewards.